Across TCGA pan-cancer cohorts, ALOX12B mass-spec protein is linked to patient survival in 1 of 34 cancer types, making it a survival-associated ALOX12B data layer compared with 21 for mass-spec protein and 10 for mutation status.
The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher ALOX12B mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated ALOX12B expression acts as an unfavorable survival marker, although some lineages such as HNSC show a favorable association.
HNSC are the cancer types where ALOX12B mass-spec protein most reproducibly stratifies survival.